Research News
View articles by month and year
-
About 25% of Women Either Don’t Start or Don’t Finish Hormonal Therapy
A study suggests that about 25% of women who are prescribed hormonal therapy to reduce the risk of recurrence after surgery either don’t start taking the medicine or stop taking it early.
-
Fareston Is Effective Against Some Advanced-Stage Cancers That Have Stopped Responding to Aromatase Inhibitors
A small study has found that Fareston is a good treatment option for postmenopausal women diagnosed with advanced-stage hormone-receptor-positive breast cancer that grew while being treated with the aromatase inhibitors Arimidex or Femara.
-
Prolia Approved by FDA to Treat Bone Loss in Women Taking Aromatase Inhibitor
The osteoporosis drug denosumab (Prolia) is now FDA-approved to treat bone loss in women taking aromatase inhibitors.
-
Is Switching Hormonal Therapies Better Than Taking Only One?
Research suggests that taking tamoxifen for 2 to 3 years and then switching to an aromatase inhibitor might be better than taking only tamoxifen or only an aromatase inhibitor for 5 years to reduce recurrence risk and improve overall survival.
-
Aromatase Inhibitors Increase Risk of Heart Problems
Women diagnosed with early-stage, hormone-receptor-positive breast cancer who got 5 years of an aromatase inhibitor seem to be more likely to have heart problems compared to women who got 5 years of tamoxifen.
-
Aromatase Inhibitor Before Surgery May Make Lumpectomy an Option
Many women diagnosed with hormone-receptor-positive, early-stage breast cancer for whom mastectomy was recommended may be candidates for lumpectomy after taking an aromatase inhibitor.
-
New Guidelines Prefer Aromatase Inhibitors Over Tamoxifen
The American Society of Clinical Oncology has issued new guidelines on taking hormonal therapy medicines after breast cancer surgery.
-
Estradiol Therapy May Help Some Advanced-Stage Breast Cancers Start Responding to Hormonal Therapy Again
A small study found that estradiol, a form of estrogen, was an effective treatment for about 30% of advanced-stage, hormone-receptor-positive breast cancers that had stopped responding to hormonal therapy.
-
Aromatase Inhibitors Slightly Better Than Tamoxifen for Postmenopausal Women
A review of a number of studies confirms that aromatase inhibitors reduce the risk of early-stage, hormone-receptor-positive breast cancer coming back better than tamoxifen in post-menopausal women.
-
Estradiol May Make Breast Cancer Start Responding to Aromatase Inhibitors Again
A small study found that estradiol, a form of estrogen, can make advanced-stage, hormone-receptor-positive breast cancers that have stopped responding to hormonal therapy start responding again in some cases.
